-
Loading metrics
Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer
- Shunsuke Tsuzuki,
- Shotaro Nakanishi,
- Mitsuyoshi Tamaki,
- Takuma Oshiro,
- Jun Miki,
- Hiroki Yamada,
- Tatsuya Shimomura,
- Takahiro Kimura,
- Nozomu Furuta,
- Seiichi Saito
x
- Published: October 1, 2021
- https://doi.org/10.1371/journal.pone.0258160